- +1-315-215-1633
- sales@thebrainyinsights.com
The global radioligand therapy market is expected to grow from USD 9.78 billion in 2022 to USD 14.91 billion by 2030, at a CAGR of 5.42% during the forecast period 2022-2030. The Asia Pacific radioligand therapy market is expected to grow the fastest during the forecast period.
The second most common cause of mortality worldwide is an extensive group of diseases known as cancer. The growth of aberrant cells is cancer. These cells penetrate body tissue and organs by rapidly forming, dividing, and multiplying. Depending on the kind and number of aberrant cells, they can either be slow or aggressive. Numerous forms of cancer include lung, colon, breast, prostate, basal cell, melanoma, and many others. According to experts, melanoma is the most dangerous kind of cancer. In some cases, various treatments available on the market can help the tumour shrink or disappear. Radioligand therapy is one such therapy. Radioligand therapy is a precision therapy which targets cancer cells through radioisotopes. The power of nuclear technology is harnessed, ridding the body of cancer cells. Its precision helps in protecting healthy cells from undesirable effects. It is a targeted therapy that improves the treatment's effectiveness and increases cancer patients' survival rate.
Get an overview of this study by requesting a free sample
November 2022 - POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, released new preclinical data from the Company’s pan-cancer fibroblast activation protein-α (FAP-α) targeted programme, PNT2004. The primary goal of the preclinical study was to evaluate the potential of 177Lu-PNT6555, the lead candidate in the PNT2004 clinical programme, in combination with anti-PD-1 immunotherapy. The CT26-mFAP tumour model expresses low levels of FAP, grows aggressively and is insensitive to anti-PD-1 immunotherapy. According to the research, 177Lu-PNT6555 and anti-PD-1 treatment given together significantly improved survival compared to receiving either medication alone.
November 2022 - POINT Biopharma Global Inc. and Lantheus Holdings, Inc., a company dedicated to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions, announced a set of strategic collaboration agreements. The agreement states that upon consummation of the agreements, in exchange for the exclusive worldwide rights1, Lantheus will pay a total of $260 million in upfront payments. In addition, Lantheus will pay 15% for PNT2003 and 20% for PNT2002 POINT royalties on net sales that exceed specific financial thresholds and are subject to conditions.
Drivers:
The increasing global cancer incidence and prevalence – Approximately 10 million cancer deaths happened in 2020. The number is expected to increase, given the new lifestyle and environmental triggers contributing to cancer's rising incidence and prevalence. A significant improvement in global healthcare is the increase in life expectancy, meaning individuals live longer in the modern world. The risk of cancer increases with age. Therefore, the growing geriatric population of the world will lead to an increasing pool of cancer patients. The long work hours and hustle culture contribute to the sedentary lifestyle and unhealthy food intake. The increasing consumption of highly processed sugary food and beverages will also contribute to the rising cancer population as obesity increases cancer risk. The growing diabetic population will also increase cancer patients. With the increase in cancer patients, the modern healthcare infrastructure offers an increasing number of treatment options. Terminal and fatal cancer encourage the patient and the doctors to acquire the latest technology, medication and therapies to treat cancer and reduce its impact on the body. Given its effectiveness, radioligand is a novel treatment method in demand for cancer patients. Therefore, the increasing number of cancer patients will drive global radioligand therapy.
Restraints:
Radioligand therapy is expensive – It costs a lot of money to create the medications and therapies used to treat cancer. The efficacy and safety of medications, therapies, and treatments are improved by market participants using the most recent technology and developments. Treatments become pricey due to the high cost of such technologies. The Company's expenses are further increased by the lengthy and numerous stages of trials and regulatory approvals. Furthermore, the use of radioisotopes in the treatment requires constant monitoring and vigilance regarding its use throughout the supply chain. The isotopes are also highly sensitive and must be handled very carefully as they have a short lifespan. The short lifespan also increases the logistical needs, further increasing the costs. The high cost of cancer immunotherapy drug discovery and outsourced therapies will hamper the market's expansion.
Opportunities:
Technological advancements are improving the effectiveness of radioligand therapy – Major businesses are expanding their investments in developing better diagnostics, medications, equipment, technologies, and treatment alternatives in response to the rising demand for cancer treatments. Radioligand therapy research has become popular, giving market participants additional opportunities to tap into its market potential. The creation of contract research firms has given market players new opportunities by enabling them to offer improved services at cheaper rates and with greater competence. Government financing for improving public healthcare facilities has expanded, fuelling further investigation into more effective treatment choices. Major market participants are collaborating and partnering to develop cutting-edge technology and diagnosis with radioligand therapy to gain a considerable market share in emerging nations. The industry will become more competitive and effective with technological breakthroughs and advancements in the radioligand therapy market, which will spur the sector's expansion and provide attractive prospects for market participants.
Challenges:
Precise and stringent rules and regulations – Many drugs, treatments and therapies are thoroughly tried, tested and put through multiple layers of monitoring and safety protocols to ensure consumer security and safeguard their interest. Radioligand therapy and its further advancements are put to various rigorous tests before it is approved in clinical cases at hospitals and clinics. The remedies must receive the appropriate authorities' approval even after successful trial findings. The authorities maintain stringent compliance and accountability standards for the same. It takes time for the market participants to undergo the inspection. Market participants waste significant time waiting for approval, which administrative issues can occasionally delay. For market participants, the wasted time results in capital losses because the window to generate above-average profits and pay for the high costs of R&D is closed. Therefore, checks and balances before approval and authorization can hamper the market's growth.
Regional segmentation analysis:
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region emerged as the largest global radioligand therapy market, with a 40.41% market revenue share in 2022. North America now holds a dominant position in the global market for radioligand therapy due to the rising incidence of cancer brought on by excessive tobacco use, smoking, poor diet, and an increase in the number of obese people. The increasing geriatric population also significantly contributes to the rising cancer patient pool. The presence of important industry players and well-known CROs in the area is also aiding the expansion of the regional market. Contract research organizations, or CROs, offer the necessary expertise and support to the pharmaceutical and biotechnology industries on a contract basis. The market for radioligand therapy is growing due to the government's increasing focus on providing patients with essential medicines at an accessible cost. In contrast, Asia-Pacific is anticipated to grow throughout the forecast period due to rising government spending on healthcare infrastructure and increased research and development activities by leading market participants.
North American region Radioligand Therapy Market Share in 2022 - 40.41%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
Indication segment analysis
The indication segment is divided into prostate cancer, neuroendocrine tumor and other indications. The prostate cancer segment dominated the market with a revenue share of around 52% in 2022. Prostate cancer affects males, and it impacts the prostate glands of the male reproductive system. The most common symptom of prostate cancer is difficulty in urination. However, early diagnosis is still difficult. Prostate cancer is amongst the top illnesses that contribute to global deaths. Around one million prostate cancer patients are diagnosed annually around the world. Every 13 men of 100 American men have prostate cancer. Around 1 in every 40 men dies of the disease. Radioligand therapy is primarily used in prostate cancer, given its effectiveness and precision. The survival rate is significantly increased with the therapy. Therefore, the growing prevalence of prostate cancer and the effectiveness of radioligand therapy in increasing these cancer patients' survival rates are driving the segment's dominance.
Product type segment analysis
The product type segment is divided into approved products and pipeline products. The approved products segment dominated the market with a market share of around 56% in 2022. A significant number of products are available in the market with approval and authorization from regulatory bodies. These treatment options have cleared the regulatory checks and have a certain degree of credibility in the market, increasing their adoption. The streamlining and fast-paced regulatory approvals by reducing redundancy are also contributing to the growing number of approved products entering the market.
Biomarker segment analysis
The biomarker segment is divided into prostate-specific membrane antigen, cytochrome P450 17A1 inhibitor and Ki 67 expression and grading. The prostate-specific membrane antigen segment dominated the market with a revenue share of around 45% in 2022. Prostate-specific membrane antigen is a highly effective novel cancer treatment for metastatic prostate cancer. Its precision enables the treatment of cancer cells without affecting healthy cells. The significant number of prostate cancer patients will drive the dominance of this segment. Technological advancements and product innovations also ensure the continuing growth of the segment.
End-user segment analysis
The end-user segment is divided into hospitals, clinics, academic & research institutes and others. The hospital segment dominated the market with a market share of around 50% in 2022. Hospitals have access to highly advanced and novel treatments. They are capitally equipped to access and afford such technologies. The growing fiscal push to improve healthcare infrastructure will also contribute and aid the hospital segment to contribute significantly to global radioligand therapy. Hospitals have dedicated oncology departments for cancer patients, including a range of services and treatments specifically offered for cancer patients.
Report Description:
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2022 | USD 9.78 Billion |
| Market size value in 2030 | USD 14.91 Billion |
| CAGR (2022 to 2030) | 5.42% |
| Historical data | 2019-2020 |
| Base Year | 2021 |
| Forecast | 2022-2030 |
| Segments | The regions examined for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa. |
| Regional Segments | The research segment is based on indication, product type, biomarker and end user. |
As per The Brainy Insights, the size of the radioligand therapy market was valued at USD 9.78 billion in 2022 to USD 14.91 billion by 2030.
Global radioligand therapy market is growing at a CAGR of 5.42% during the forecast period 2022-2030.
The market's growth will be influenced by the increasing global cancer incidence and prevalence.
The radioligand therapy is expensive could hamper the market growth.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis by Indication
4.3.2. Market Attractiveness Analysis by Product Type
4.3.3. Market Attractiveness Analysis by Biomarker
4.3.4. Market Attractiveness Analysis by End User
4.3.5. Market Attractiveness Analysis by Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. The increasing global cancer incidence and prevalence
5.3. Restraints
5.3.1. Radioligand therapy is expensive
5.4. Opportunities
5.4.1. Technological advancements are improving the effectiveness of radioligand therapy
5.5. Challenges
5.5.1. Precise and stringent rules and regulations
6. Global Radioligand Therapy Market Analysis and Forecast, By Indication
6.1. Segment Overview
6.2. Prostate Cancer
6.3. Neuroendocrine Tumor
6.4. Other Indications
7. Global Radioligand Therapy Market Analysis and Forecast, By Product Type
7.1. Segment Overview
7.2. Approved Products
7.3. Pipeline Products
8. Global Radioligand Therapy Market Analysis and Forecast, By Biomarker
8.1. Segment Overview
8.2. Prostate-Specific Membrane Antigen
8.3. Cytochrome P450 17A1 Inhibitor
8.4. Ki 67 Expression and Grading
9. Global Radioligand Therapy Market Analysis and Forecast, By End User
9.1. Segment Overview
9.2. Hospitals
9.3. Clinics
9.4. Academic & Research Institutes
9.5. Others
10. Global Radioligand Therapy Market Analysis and Forecast, By Regional Analysis
10.1. Segment Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.5. South America
10.5.1. Brazil
10.6. Middle East and Africa
10.6.1. UAE
10.6.2. South Africa
11. Global Radioligand Therapy Market-Competitive Landscape
11.1. Overview
11.2. Market Share of Key Players in the Radioligand Therapy Market
11.2.1. Global Company Market Share
11.2.2. North America Company Market Share
11.2.3. Europe Company Market Share
11.2.4. APAC Company Market Share
11.3. Competitive Situations and Trends
11.3.1. Product Launches and Developments
11.3.2. Partnerships, Collaborations, and Agreements
11.3.3. Mergers & Acquisitions
11.3.4. Expansions
12. Company Profiles
12.1. Bayer AG
12.1.1. Business Overview
12.1.2. Company Snapshot
12.1.3. Company Market Share Analysis
12.1.4. Company Product Portfolio
12.1.5. Recent Developments
12.1.6. SWOT Analysis
12.2. ITM Isotope Technologies Munich SE
12.2.1. Business Overview
12.2.2. Company Snapshot
12.2.3. Company Market Share Analysis
12.2.4. Company Product Portfolio
12.2.5. Recent Developments
12.2.6. SWOT Analysis
12.3. Janssen Global Services LLC
12.3.1. Business Overview
12.3.2. Company Snapshot
12.3.3. Company Market Share Analysis
12.3.4. Company Product Portfolio
12.3.5. Recent Developments
12.3.6. SWOT Analysis
12.4. Johnson & Johnson Services Inc.
12.4.1. Business Overview
12.4.2. Company Snapshot
12.4.3. Company Market Share Analysis
12.4.4. Company Product Portfolio
12.4.5. Recent Developments
12.4.6. SWOT Analysis
12.5. Molecular Partners
12.5.1. Business Overview
12.5.2. Company Snapshot
12.5.3. Company Market Share Analysis
12.5.4. Company Product Portfolio
12.5.5. Recent Developments
12.5.6. SWOT Analysis
12.6. Novartis International AG
12.6.1. Business Overview
12.6.2. Company Snapshot
12.6.3. Company Market Share Analysis
12.6.4. Company Product Portfolio
12.6.5. Recent Developments
12.6.6. SWOT Analysis
12.7. Pfizer Inc.
12.7.1. Business Overview
12.7.2. Company Snapshot
12.7.3. Company Market Share Analysis
12.7.4. Company Product Portfolio
12.7.5. Recent Developments
12.7.6. SWOT Analysis
12.8. POINT Biopharma Global Inc.
12.8.1. Business Overview
12.8.2. Company Snapshot
12.8.3. Company Market Share Analysis
12.8.4. Company Product Portfolio
12.8.5. Recent Developments
12.8.6. SWOT Analysis
12.9. Radio Medix
12.9.1. Business Overview
12.9.2. Company Snapshot
12.9.3. Company Market Share Analysis
12.9.4. Company Product Portfolio
12.9.5. Recent Developments
12.9.6. SWOT Analysis
12.10. Telix Pharmaceuticals
12.10.1. Business Overview
12.10.2. Company Snapshot
12.10.3. Company Market Share Analysis
12.10.4. Company Product Portfolio
12.10.5. Recent Developments
12.10.6. SWOT Analysis
List of Table
1. Global Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
2. Global Prostate Cancer Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
3. Global Neuroendocrine Tumor Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
4. Global Other Indications Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
5. Global Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
6. Global Approved Products Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
7. Global Pipeline Products Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
8. Global Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
9. Global Prostate-Specific Membrane Antigen Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
10. Global Cytochrome P450 17A1 Inhibitor Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
11. Global Ki 67 Expression and Grading Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
12. Global Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
13. Global Hospitals Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
14. Global Clinics Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
15. Global Academic & Research Institutes Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
16. Global Others Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
17. Global Radioligand Therapy Market, By Region, 2019-2030 (USD Billion)
18. North America Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
19. North America Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
20. North America Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
21. North America Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
22. U.S. Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
23. U.S. Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
24. U.S. Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
25. U.S. Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
26. Canada Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
27. Canada Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
28. Canada Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
29. Canada Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
30. Mexico Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
31. Mexico Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
32. Mexico Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
33. Mexico Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
34. Europe Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
35. Europe Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
36. Europe Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
37. Europe Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
38. Germany Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
39. Germany Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
40. Germany Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
41. Germany Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
42. France Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
43. France Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
44. France Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
45. France Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
46. U.K. Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
47. U.K. Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
48. U.K. Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
49. U.K. Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
50. Italy Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
51. Italy Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
52. Italy Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
53. Italy Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
54. Spain Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
55. Spain Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
56. Spain Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
57. Spain Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
58. Asia Pacific Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
59. Asia Pacific Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
60. Asia Pacific Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
61. Asia Pacific Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
62. Japan Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
63. Japan Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
64. Japan Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
65. Japan Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
66. China Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
67. China Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
68. China Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
69. China Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
70. India Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
71. India Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
72. India Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
73. India Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
74. South America Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
75. South America Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
76. South America Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
77. South America Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
78. Brazil Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
79. Brazil Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
80. Brazil Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
81. Brazil Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
82. Middle East and Africa Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
83. Middle East and Africa Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
84. Middle East and Africa Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
85. Middle East and Africa Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
86. UAE Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
87. UAE Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
88. UAE Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
89. UAE Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
90. South Africa Radioligand Therapy Market, By Indication, 2019-2030 (USD Billion)
91. South Africa Radioligand Therapy Market, By Product Type, 2019-2030 (USD Billion)
92. South Africa Radioligand Therapy Market, By Biomarker, 2019-2030 (USD Billion)
93. South Africa Radioligand Therapy Market, By End User, 2019-2030 (USD Billion)
List of Figures
1. Global Radioligand Therapy Market Segmentation
2. Radioligand Therapy Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Radioligand Therapy Market Attractiveness Analysis by Indication
9. Global Radioligand Therapy Market Attractiveness Analysis by Product Type
10. Global Radioligand Therapy Market Attractiveness Analysis by Biomarker
11. Global Radioligand Therapy Market Attractiveness Analysis by End User
12. Global Radioligand Therapy Market Attractiveness Analysis by Region
13. Global Radioligand Therapy Market: Dynamics
14. Global Radioligand Therapy Market Share by Indication (2022 & 2030)
15. Global Radioligand Therapy Market Share by Product Type (2022 & 2030)
16. Global Radioligand Therapy Market Share by Biomarker (2022 & 2030)
17. Global Radioligand Therapy Market Share by End User (2022 & 2030)
18. Global Radioligand Therapy Market Share by Regions (2022 & 2030)
19. Global Radioligand Therapy Market Share by Company (2021)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the radioligand therapy market based on below mentioned segments:
Radioligand Therapy Market by Application:
Radioligand Therapy Market by Product Type:
Radioligand Therapy Market by Biomarker:
Radioligand Therapy Market by End User:
Radioligand Therapy Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
